Mazindol for Cocaine Abuse - 2

This study has been completed.

First Received on September 20, 1999. Last Updated on June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	VA Connecticut Healthcare System
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000277

Purpose

The purpose of this study is to evaluate high and low dose mazindol for cocaine abuse.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Mazindol	Phase II

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Mazindol for Cocaine Abuse

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride Mazindol

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Side effects
Drug use
Retention

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000277

Locations

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

VA Connecticut Healthcare System

Investigators

Principal Investigator:

Thomas R Kosten, M.D.

VA Connecticut Healthcare System

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00000277 History of Changes
Other Study ID Numbers:	NIDA-09250-2, P50-09250-2
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Mazindol
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents

Therapeutic Uses
Adrenergic Uptake Inhibitors
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors
Dopamine Agents

ClinicalTrials.gov processed this record on February 09, 2012